卵巢恶性肿瘤患者保留生育功能治疗的预后及相关因素分析

目的探讨3种不同类型卵巢恶性肿瘤患者保留生百功能治疗的颁后及其相关因素。方法回顾性分析189例保留生育功能治疗的卵巢恶性肿瘤患者的生存率、复发与未控率、生育状况等情况。189例中生殖细胞肿瘤（OGCT）136例,性索间质肿瘤（OSCST）31例,上皮性癌（EOC）22例。对OGCT、OSCST、EOC3组患者的中位随访时间分别为50、46、45个月。结果OGCT、OSCST、EOC3组患者的5年生存率分别为94．0％（131／134）、77．1％（26／30）、64．7％（16／21）,复发与未控率分别为29．9％（40／134）、20．0％（6／30）、47．6％（10／21）,随访期内共有46例次的患者分娩。规范化疗是影响OGCT生存率及复发与未控率的独立因素;对于OSCST,FIGO分期、规范化疗分别是影响生存率和复发与未控率的因素。全面分期手术及FIGO分期是影响EOC生存率和复发与未控率的因素。结论保留生育功能治疗对于OSCST和EOC需强调个体化,而对于OGCT则不受FIGO分期限制。治疗结局以OGCT最好,OSCST次之,EOC最差。

Analysis of prognostic factors of malignant ovarian tumor after fertility-preserving treatment

Objective To explore the prognostic factors of malignant ovarian tumor after fertility-preserving treatment. Methods 189 patients with malignant ovarian tumor who had undergone fertility-preserving management in the past 20 years were retrospectively analyzed. The correlative factors for survival, recurrence and reproductive status were evaluated. Among the patients, 136 cases suffered from ovarian germ cell tumor (OGCT), 31 cases suffered from ovarian sex cord-stromal tumor (OSCST), and 22 cases suffered from epithelial ovarian cancer (EOC). The median follow-up time of different groups was 50 months for OGCT, 46 months for OSCST, 45 months for EOC respectively. Results The 5-year survival rates for OGCT, OSCST and EOC groups were 94.0%(131/134), 77.1%(26/30) and 64.7%(16/21) respectively. The recurrent rates were 29.9%(40/134), 20.0%(6/30) and 47.6% (10/21) respectively. 46 babies were deliveried during the follow-up period. Standard chemotherapy was the most important prognostic factor for OGCT. FIGO stage and standard chemotherapy were favourable factors for prognosis in OSCST group. The important prognostic factors included FIGO stage and standard comprehensive surgical staging for EOC. Conclusion Fertility-preserving treatment should be considered for OGCT without limitation of FIGO stage, whereas it should be performed individually for OSCST and EOC. The treatment outcome for OGCT is the best, for EOC the worst.